Objective: Aim of this study is to evaluate anti-nuclear antibody (ANA) test results obtained between 2009 and 2011.
Medizinische Labordiagnostica AG, Germany) was used for screening ANA. Test was performed with 1/100 dilution of the serum samples. The results were reported as negative or positive with the fluorescence levels and patterns like homogeneous, granular, nucleolar, etc.
Detection of anti-dsDNA levels
ELISA (Organtec Diagnostika GmbH, Germany) was performed for testing anti-ds DNA. Levels above 20 IU/mL were considered positive according to the test protocol.
Detection of anti-ENA profiles
Immunblotting was done by using Euroline Anti ENA profile plus 1 IgG assay (Euroimmun Medizinische Labordiagnostica AG, Germany).
All tests were performed by using the instructions in the kit inserts.
RESULTS
Gender distribution of ANA positive patients was determined as 756 (77%) females and 226 (23%) males. Table 1 shows the distribution of ANA positive patients to the medical departments. The majority of the ANA positive patients were from rheumatology (50%), gastroenterology (20%) and physical medicine and rehabilitation (5%) departments. Other ANA positive patients were from pulmonary diseases, dermatology, neurology, internal diseases, hematology, nephrology, infectious diseases, endocrinology and other departments.
The fluorescence levels and the patterns of ANA positive samples were shown in Table 2 and 3 respectively. The most frequent four patterns were homogeneous (23%), granular (22%), homogeneous-granular (15.5%) and nucleolar (13.5%) in our study. The majority of ANA positive samples (62.6%) had only borderline or weak fluorescence level in our study. The indicative fluorescence levels were found as; 1+ (24.5%), 2+ (7%), 3+ (3.3%) and 4+ (2.3%).
INTRODUCTION
Anti-nuclear antibody (ANA) is a common name for the antibodies against the contents of the cell nucleus. The detection of ANA is used as screening test for the diagnosis of autoimmune diseases especially for rheumatologic disorders. Approximately 25% of the community has ANA positivity but the prevalence of significantly elevated levels is about 2.5% which indicates an autoimmune disease. The gold standard for the detection of ANA is indirect immune-fluorescence assay (IIFA) that has a lot of advantages like the patterns which indicate certain diseases. [1] [2] [3] There are three types of patterns; nuclear (homogeneous, granular, nuclear lamine, centromeric, nuclear dots, proliferating cell nuclear antigen), cytoplasmic (granular, filaments like actin, vimentin, cytokeratin, lysosomal-like, Golgi apparatus) and mitotic (spindle, midbody, centrosomoses). As the antibodies not only against to the nuclear parts but also cytoplasmic and mitotic elements, the terminology of ANA was discussed for a change to appropriate term like anticellular antibodies. 4, 5 After a positive result, a further examination is done with anti-double stranded DNA (anti-dsDNa) and antiextractable nuclear antigen (anti-ENA) profile which contain specific antigens like SSA/Ro, SSB/La, Sm, Scl-70 for clarifying the diagnosis. [1] [2] [3] [4] [5] [6] The aim of this study is to look for features of ANA results including gender and department of the patients, ratio of positiveness, fluorescence titre levels and patterns, anti-dsDNA and anti-ENA profiles during a three year period. Anti-dsDNA was ordered from 759 out of 982 (77.3 %) ANA positive patients; 66 (8.7%) of them were positive. Homogenous pattern was determined in 44 (68.8%) anti-dsDNA positive samples. Granular, nucleolar, nuclear dots, centromeric and midbody patterns were determined from the rest of the positives.
Anti-ENA profile was ordered from 414 (42%) of the ANA positive patients and 131 (31.6%) of them were found positive. The distribution of the extractable anti-nuclear antigens was shown in Table  4 . According to our study, the most frequent four antigens were SSA (34.4%), SSA-SSB (16.8%), Scl70 (16%) and Sm/RNP (9.2%) respectively. 
DISCUSSION
The autoantibodies which are seen in autoimmune diseases are against to nuclear and cytoplasmic components of the cells. The target antigens are ribonucleoproteins for anti-Sm, anti-RNP, anti-SSA/ Ro, anti-SSB/La; DNA topoisomerase Type 1 for anti-Scl70; centromere for anti-centromere transfer; histidyl-tRNA synthetase for Jo-1 and doublestranded DNA for anti-dsDNA. 1 Autoantibody detection tests have been used for the diagnosis and to monitor the therapy of the autoimmune diseases for almost 50 years. Today, autoantibody detection is done mostly by ready to use, economic and standardized commercial tests. which is the major test to find an autoimmune disease. 7 ANA positivity rate found in our female patients (77%) is consistent results with the knowledge of the autoimmune diseases are more frequent in women. 8, 9 This predominance was researched by Leo and et al. According to their study, the hormone profile, fetal microchimerism and some strategic genes which are on the sex chromosomes are playing role on this relationship. 10 As expected, the most of the positive ANA results were from rheumatology department (50%) in our study. This result is similar with the recent study of Karakeçe et al. which was done in an university hospital in Turkey. 11 ANA is a very valuable test for the diagnosis of SLE (93% sensitivity) and scleroderma (85% sensitivity). It is also important for diagnosing Sjögren's syndrome, secondary Raynaud, polymyositis/dermatomyositis and rheumatoid arthritis.
12 Surprisingly, the second frequent ANA positivity rate was in patients of the gastroenterology department (20%) in our study. The presence of ANA is found in a lot of chronic hepatobiliary diseases like viral hepatitis, drug induced hepatic disease, primary biliary cirrhosis, primary sclerosing cholangitis, non-alcoholic steatohepatitis, and alcoholic hepatitis. The main reason of ANA positivity is not the stimulation by an immunogen but the destruction of the hepatic cells because of the inflammation and necrosis. ANA is a very important diagnostic criterion especially in type 1-autoimmune hepatitis, along with anti-smooth muscle cell antibody. The most frequent patterns are homogeneous and granular in autoimmune hepatitis and nuclear lamine is the second one. [13] [14] [15] Of all ANA positive samples, 62.6% had only borderline or weak fluorescence level in this study. As the clinical association of borderline/weak fluorescence levels are a subject of discussion, some researchers did not reported because they accepted as negative. Low titers of autoantibodies are seen in healthy people, relatives of the autoimmune patients and patients who have chronic inflammatory disease or cancer without having an autoimmune base. These kinds of antibodies are usually in IgM type of low affinity and polyreactive. 16 Most of the ANA positive people don't developed an autoimmune disease and this is consisted with low prevalence of rheumatologic disorders (5-7%) despite the rate of ANA presence. 9 ANA positivity can be detected 20-30% at 1/40, 10% at 1/80 and 5% at 1/160 dilution in healthy people. 17 Li et al. suggest that the persistence of the positive ANA may be a part of the component of the normal immune response. 9 In the study of Mariz et al., ANA positive healthy people were followed up for four years of period and none of them developed any symptoms. Along the period, 72.5% of the ANA positivity persisted on the same level, while 27.5% of them dropped below 1/80 and were reported as negative. It has been emphasized that this follow up was done only from the healthy people who had ANA-Hep-2 patterns that were not specific for acute rheumatic diseases. The writers suggested that the low ANA positivity of the patterns like homogeneous and centromere which are related only to autoimmune diseases must be followed intensely. 18 The common recommendation is to report the fluorescence levels above 1+ as positive. The increase of ANA by age was proved by several studies. 16, 19 In our laboratory, IIFA is performed at 1/100 dilution and all patterns even with the borderline fluorescence level are reported and the judgment of the importance of the positivity is left to the clinicians. This type of reporting might give a chance to the SLE patients whose ANA is positive considerably before the clinical symptoms which is not a rare probability and these patients must be followed carefully. 20 Of all ANA positive patients with borderline/weak fluorescence level, 43.3% were from rheumatology department in this study.
The most frequent four patterns were homogeneous (23%), granular (22%), homogeneous-granular (15.5%) and nucleolar (13.5%) in this study. This was similar with the results of other studies from Turkey. Güdücüoğlu et al. reported 152 homogeneous, 96 nucleolar, 82 granular pattern out of 367 ANA positive patients. 8 The most and dominantly seen pattern was found as homogeneous (51.2%) and this was followed by fine granular (6%), homogeneous/fine granular (6%) and homogeneous/ nucleolar (6%) by Yılmaz et al. [1] . Likewise, Yumuk et al. reported homogeneous as the most frequent pattern and the second one was granular. 21 Also Karakeçe et al. found the most frequent patterns as nuclear (56.2; fine and coarse granular, homogeneous and nuclear membrane), nucleolar (16.2%), mitotic (14%) and cytoplasmic (13.6%).
11
A new pattern is identified showing a nuclear distribution of dense fine speckles (DFS) also known as lens epithelium-derived growth factor p75 (LEDGF/p75) that recognized as a 70-kd protein was not distinguished from homogeneous-granular pattern at the time of the study. Some of the homogeneous-granular patterns will be change into Anti-dsDNA was positive in 8.7% of ANA positive patients in the study. The major pattern of anti-dsDNA positive samples was homogeneous (68.8%). The most seen pattern from SLE disease is homogeneous (60-70%) which shows the autoantibody presence against dsDNA and our results were parallel to the literature. 1, 21, 24 On the other hand, it must be considered that homogeneous pattern may also point to the autoantibodies against histon and nucleosomes. The presence of anti-dsD-NA has prognostic value as the titer of anti-dsDNA is an important criterion of disease activity and also shows a correlation with lupus nephritis. [24] [25] [26] First step of the algorithm of ANA and specific antibody testing in the diagnosis of rheumatic diseases is to screen ANA. The second step is testing for anti-ENA profile from positive samples. Anti-ENA profile test is an immunoblotting assay that uses only known antigens. [27] [28] [29] Therefore, ANA with IIFA is more sensitive than anti-ENA profile test. According to our study, the most frequent four antigens were SSA (34.4%), SSA-SSB (16.8%), Scl70 (16%) and Sm/RNP (9.2%) respectively. Anti-Sm antibodies are mostly found in SLE patients but they can only detected in 25-30% of them. Similarly, Scl70 is 100% specific for the diagnosis of systemic sclerosis. If SSA or/and SSB are detected, the result will direct us not only to diagnose Sjögren's syndrome but also to sub acute cutaneous SLE and neonatal lupus syndrome. 30 Some studies reported that some ENAs especially anti-SSA/Ro and anti-SSB/ La antibodies can be missed on IIFA, although others demonstrated borderline fluorescence might contain these antibodies. 31 It should not be forgotten that anti-ENA profile may be negative depending on the positive ANA pattern.
Our three years' experience of testing autoantibodies was shared in this study. Reliable test results are very important for the health of the patients with autoimmune disorders. For being a dependable laboratory, having enough knowledge and experience about the chosen methods of autoantibody tests is mandatory. It should be remembered that clinic status of the patients are very important for considering the results of autoimmune tests especially ANA. 32 A good relationship with the clinicians is also an indispensable component of confidential analysis and reporting.
